The CanREValue Collaboration is excited to share our latest publication – Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration. An online version of this paper is available through Current Oncology at https://www.mdpi.com/1718-7729/30/4/286  Abstract (more…)

We are happy to announce that CanREValue’s latest publication, Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer, has been accepted for publication in JAMA Network Open. Download a copy of this paper. Abstract IMPORTANCE: To date, limited studies (more…)

We are happy to announce that CanREValue’s latest publication, Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group, has been accepted for publication in Current Oncology. Download a copy of this paper. Abstract The Canadian (more…)

As part of a broader engagement strategy, the CanREValue Collaboration has launched a stakeholder consultation process. In 2020, the CanREValue Collaboration undertook public stakeholder consultation regarding the Interim Methods Report developed by the CanREValue Methods Working Group. From this consultation, we received 13 constructive submissions from a diverse set of (more…)

As part of a broader engagement strategy, the CanREValue Collaboration has launched a stakeholder consultation process. In late 2019, the CanREValue Collaboration undertook public stakeholder consultation regarding the Interim Data Report developed by the CanREValue Data Working Group. From this consultation, we received 20 constructive submissions from a diverse set (more…)